Biomedical Research · 2013 · 19 citations · 20 references
MedicineOncologyPharmacologyChemotherapyGynecologic OncologyMolecular OncologyCancer BiomarkersEndometrial CancerMalignant NeoplasmsMolecular Tumor ProfilingCopper Transporter 1 (Ctr1)Disease-free Survival AnalysisDisease-free Survival AssessmentEndometrial Cancer ChemotherapyPrognostic VariablesTumor Uptake MechanismsType I Endometrial CancerUnivariate Analysis
Paclitaxel and carboplatin (TC) chemotherapy is an effective and well-tolerated regimen against advanced endometrial cancer. Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively. This study aimed to address the prognostic impact of OATP1B3 and CTR1 in endometrial cancer patients treated with adjuvant TC chemotherapy. We immunohistochemically evaluated the expressions of OATP1B3 and CTR1 in 47 stage III endometrial cancers. The high expression levels of OATP1B3 were significantly correlated with type I tumor (P = 0.0005). In univariate analysis, high expression levels of OATP1B3 (P = 0.047) and CTR1 (P = 0.009) were significantly associated with longer disease-free survival (DFS) and longer overall survival (OS), respectively. The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially longer DFS (P = 0.058) and significantly longer OS (P = 0.003) sin the univariate analysis. Combined OATP1B3/CTR1 expression was the sole independent prognostic factor for longer OS in the multivariate analysis (P = 0.013). Our findings suggest that combined OATP1B3/CTR1 expression is a possible predictive/prognostic factor for a good outcome in stage III endometrial cancer patients treated with adjuvant TC chemotherapy.
20
Rebecca L. Siegel, Elizabeth Ward, Otis W. Brawley et al. · CA A Cancer Journal for Clinicians · 2011 · 4.1K citations · Full text
Two pathogenetic types of endometrial carcinoma
Jan V. Bokhman · Gynecologic Oncology · 1983 · 2.5K citations
Medicine, Gynecology, Oncology +13